Boehringer expands commercial biologics production capacity in China
Boehringer will increase its capacity for commercial manufacturing of biologics at its Shanghai, China, facility.
Archives for January 22, 2019
UPDATE
Industry in conflict over generic and biosimilar manufacturing waiver
European generics industry faces opposition while pushing for the SPC manufacturing waiver to be altered so it allows for the production of drugs under patent for non-EU countries.
Sanofi licenses bi- and multi-specific antibody platform
Sanofi entered an agreement for the discovery and development of antibodies via Biomunex antibody platform.